NCT00480584View on ClinicalTrials.gov

A Phase I Trial of Capecitabine in Combination With Gemcitabine and Erlotinib for Advanced Pancreatic Cancer

PHASE1CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

April 30, 2007

Primary Completion Date

November 30, 2012

Study Completion Date

November 30, 2012

Conditions
Metastatic Pancreatic Carcinoma
Interventions
DRUG

gemcitabine

Levels 1 through 4: 1000 mg/m\^2

DRUG

capecitabine

Level 1: 500 mg/m\^2; Level 2: 825 mg/m\^2; Level 3: 1000 mg/m\^2; Level 4: 1250 mg/m\^2

DRUG

erlotinib

Levels 1 through 4: 100 mg

Trial Locations (1)

33612

H. Lee Moffitt Cancer Center & Research Institute, Tampa

Sponsors

Collaborators (1)

Genentech, Inc.
All Listed Sponsors
collaborator

Genentech, Inc.

INDUSTRY

lead

H. Lee Moffitt Cancer Center and Research Institute

OTHER